Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Ovarian Cancer
100%
Solid Tumors
100%
Tumor Regression
100%
Synergistic Therapy
100%
Layer-by-layer Nanoparticles
100%
High-grade Serous Ovarian Cancer (HGSOC)
66%
Drug Combination
66%
Tumor Cells
33%
B-cell Lymphoma 2 (Bcl-2)
33%
Chemotherapy Resistance
33%
Myeloid Cell leukemia-1 (Mcl-1)
33%
Bcl-xL
33%
Disease Resistance
16%
Pathway Inhibitors
16%
Ovarian Tumor
16%
Tumor Metastasis
16%
Cancer Tumor
16%
Cancer Model
16%
Drug Efficacy
16%
Recurrent Disease
16%
Intraperitoneal Injection
16%
Synergistic Cytotoxicity
16%
Anti-apoptotic Proteins
16%
Systemic Toxicity
16%
Near-complete
16%
Patient Morbidity
16%
Potent Drugs
16%
Free Drug
16%
Resistant Disease
16%
Complete Elimination
16%
Co-encapsulation
16%
Ovarian Cancer Xenograft
16%
Selective Uptake
16%
Oncology Drugs
16%
Co-inhibition
16%
LbL Assembly
16%
ABT-263
16%
S63845
16%
Mcl-1 Inhibitor
16%
Medicine and Dentistry
Combination Therapy
100%
Ovarian Cancer
100%
Solid Malignant Neoplasm
100%
Tumor Regression
100%
Nanoparticle
100%
Combination Drug
66%
Tumor Cell
33%
Oncology
16%
In Vitro
16%
Metastatic Carcinoma
16%
Xenograft
16%
Ovarian Tumor
16%
Recurrent Disease
16%
Antiapoptotic
16%
Intraperitoneal Drug Administration
16%
Cytotoxicity
16%
Diseases
16%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Ovary Cancer
100%
Nanoparticle
100%
Tumor Regression
100%
Combination Therapy
100%
Combination Drug
66%
Chemotherapy
33%
Elimination
16%
Antiapoptotic
16%
Ovary Tumor
16%
Recurrent Disease
16%
Intraperitoneal Injection
16%
Neoplasm
16%
Cytotoxicity
16%
Diseases
16%